Over the past few years, taking innovative
medicines global has become a much more established end-to-end process.
Once a drug reaches the clinical stage,
companies may begin preparing for overseas regulatory filings. With data in
hand, they start approaching potential overseas partners. Then come license-out
negotiations, due diligence, national-phase filings, regulatory submissions,
and eventually commercialization.
Many companies are now familiar with this
path.
Yet in real-world projects, one step is
often left until surprisingly late: patent translation.
A patent may not be sent to the translation
team until a potential partner begins due diligence. A local-language version
may not be prepared until the company has decided to enter a particular
country. And terminology may not be standardized across files until patent
counsel sends back comments for revision.
When the project is still relatively small,
this approach may not cause any obvious problems.
But as Chinese innovative medicines enter
international licensing and global development programs more frequently,
patents are becoming harder to treat as simply “documents that need to be
translated.”
They are better understood as technical
assets that need to be managed and maintained over the long term.
1. The $110 Billion Milestone Signals a New Phase for
Innovative Drugs Going Global
The shift is visible first in the deal
data.
Data disclosed by China’s National Medical
Products Administration (NMPA) show that from January through June 2026,
Chinese innovative drug companies entered into 81 overseas licensing deals,
with potential aggregate deal value of approximately US$110 billion. That
figure was already equivalent to 80% of the full-year total for 2025, setting
another record high. The deals covered 10 therapeutic areas, including
oncology, metabolic diseases, immunology, and neurology, with major licensees
based in 20 countries and regions, including the United States, the United
Kingdom, France, and Italy.
Behind those numbers is a deeper change:
international partnerships around innovative medicines are becoming more
sophisticated.
In the past, a company might have sought a
licensee primarily for a specific overseas market. Today, more deals are built
around co-development, regional rights, and commercialization across multiple
markets. As overseas partners engage more deeply with an innovative drug, the
volume and range of materials they need to review also grows.
Patent documents are naturally being read
by more than the company’s own patent counsel.
Business development teams need them. The
partner’s IP team needs them. External counsel may need them. Once the project
enters the national phase in different jurisdictions, local patent agents and
examiners will continue working with them as well.
That raises a very practical question: can
the same technology remain consistent across patent documents written in
different languages, different versions, and different national phases?
That matters far more than whether a
translation simply reads smoothly.
2. Policy Changes Are Also Pushing These Requirements
Earlier
The policy environment is moving in the
same direction.
Issued in July 2026, the 15th Five-Year
Plan for Intellectual Property Protection and Utilization calls for continued
improvement of the mechanism for early resolution of pharmaceutical patent
disputes, stronger protection of intellectual property rights in cross-border
contexts, and support for domestic innovators in pursuing overseas patent
applications through multiple channels and at a higher level of quality. It
also calls for stronger patent portfolio planning and full-process IP
management for major science and technology innovation projects.
For innovative drug companies expanding
overseas, these measures point to an increasingly clear direction: patent
management is moving beyond individual applications and individual countries
toward more coordinated planning across a longer time horizon and a broader
geographic footprint.
Overseas patent strategy needs to be
considered at the application stage. A transaction may later trigger due
diligence. Once commercialization begins, companies must deal with different IP
rules across jurisdictions. Patent disputes and enforcement may follow further
down the road.
Language is becoming increasingly difficult
to treat as the final step in the process.
The amendments to the Guidelines for Patent
Examination, which took effect on January 1, 2026, also further clarify the
information published for pharmaceutical patent term compensation, including
the drug name and approved indications.
Under the current rules, eligible invention
patents related to a new drug may be granted patent term compensation. The
request must be filed within three months from the date on which the new drug
obtains marketing authorization in China. The compensation period may not
exceed five years, and the total effective patent term after the new drug is
approved for marketing may not exceed 14 years. During the compensation period,
the scope of patent protection is limited to technical solutions related to the
new drug and its approved indications.
These provisions are not directly about how
patent documents should be translated. But together, they reinforce an
important point: the technical scope of a patent, the approved indications, the
claims, and the relationships between different documents all need to be
handled with precision. They are not areas where “close enough” is good enough.
Once those same elements move across
languages, another layer of risk is added.
3. The Problems Are Often Hidden in the Smallest Details
Anyone who has worked on an innovative
pharmaceutical patent project will probably recognize the situation.
The full specification is translated. Every
sentence looks reasonably clear on its own. Yet the final review still takes a
surprising amount of time, simply because a handful of seemingly minor details
have to be checked again and again.
Take a compound, for example.
The same compound may appear under a
development code, a chemical name, a generic name, and descriptions related to
its structure. For biologics, the documentation may also include antibodies,
amino acid sequences, nucleotide sequences, and sequence listing identifiers.
In ordinary technical documents, it may be
enough for readers to understand that different names refer to the same entity.
Patents are less forgiving.
A change in the position of a substituent,
a discrepancy in a numerical range, turning “at least” into “about,” or
rendering “consisting essentially of” in a way that makes the expression
broader or narrower than intended can break the correspondence between
different parts of the text.
Claims are another obvious example.
Expressions such as “comprising,”
“consisting of,” and “consisting essentially of” are not interchangeable. The
same applies to qualifiers such as “about,” “at least,” “no more than,” and “in
the range of.” Each has its own context and implications in patent drafting.
The difficult part is that these issues may
not produce any obvious grammatical error in the translated text.
They often only become visible when patent
family members are compared side by side and the same technical feature turns
out to have been expressed differently across versions.
Medical-use claims can be just as
sensitive.
The scope of protection for a drug may be
closely tied to the specific disease, patient population, dosing regimen, dose
range, or other elements of the intended use. Requirements for medical-use
claims also vary across jurisdictions.
That is why multilingual patent translation
is not simply a matter of replacing Chinese sentences with sentences in another
language.
The appropriate claim format for a
particular jurisdiction should be determined by local patent counsel based on
the applicable law. The translation team’s role is to accurately convey the
technical facts, relationships between the texts, and established
terminology—without introducing changes to the original meaning.
4. The Hardest Situation Is Often the Same Project Being
Translated Again and Again
Another issue that is easy to underestimate
in innovative pharmaceutical patent work is repetition.
The same drug may be covered by a Chinese
application, a PCT application, a U.S. national-phase application, European
filings, and later divisional, continuation, or other related applications.
The same technical content may also appear
repeatedly across patents, clinical materials, regulatory submissions,
due-diligence documents, and technology-transfer materials.
When every translation starts from scratch,
the larger the project becomes, the easier it is for terminology to drift.
A mechanism of action may be described one
way in the first file and differently in the next. The same indication may
appear under two different names. An experimental method may end up with
different translations in different documents.
Each individual file may still look
perfectly acceptable.
Taken together, however, the project
becomes increasingly difficult to manage.
That is why the long-term asset created
through pharmaceutical patent translation should not be limited to a collection
of translated documents. It should also include a continuously maintained
terminology base, correspondence across patent family members, core sentence
patterns, and version history.
For high-frequency content such as compound
names, targets, indications, routes of administration, dosage forms, analytical
methods, and sequence identifiers, the earlier these elements are standardized,
the less time will be spent correcting inconsistencies later.
For an innovative drug project targeting
multiple overseas markets, these assets may ultimately be more valuable than
any single translation assignment.
5. Can AI Handle It? Yes—but Its Role Matters
Today, pharmaceutical companies often ask
the same question: patent documents are long and numerous, so why not send
everything to AI first?
From an efficiency perspective, they can.
When terminology assets, historical
translations, and comparable patent materials are already well organized, AI
can take on a substantial amount of the groundwork, including terminology
retrieval, repetitive sentence handling, first-draft generation, and searches
across historical content.
The point that requires caution is the
assumption that AI can generate a translation and therefore the AI-generated
translation can be filed directly as a patent document.
Those are two very different propositions.
In innovative pharmaceutical patents, the
areas that deserve the most human attention are often the areas where errors
are least acceptable: claims, core embodiments, numerical conditions, sequence
listings, critical technical features, and consistency with existing patent
family members.
The real question is usually not whether a
sentence sounds natural.
It is whether a term has changed the scope
of a limitation. Whether a number has shifted. Whether a technical term still
corresponds to the terminology used in an earlier member of the same patent
family.
So rather than asking whether “AI can
translate patents,” it makes more sense to look at different parts of the
document separately.
Core claims and critical technical content
should remain primarily subject to professional human translation and review.
Highly repetitive and structurally stable content can make greater use of AI
and translation technology. On top of that, terminology, numerical values,
cross-references, and patent-family consistency should be checked
systematically.
The goal is not simply to reduce the amount
of human work.
It is to make sure human expertise is
concentrated where professional judgment matters most.
6. For Innovative Drug Companies, Translation Should Start
at Three Key Points
6.1. Before Overseas BD Begins
Once a potential partner enters due
diligence, patent documents may become part of the review of the company’s
technical assets.
At that point, asking a translation team to
prepare an English version at short notice often means the project has already
entered rush mode.
Organizing the core patents, patent family
materials, and terminology assets in advance can make the later stages much
easier to manage.
6.2. Before Entering the National Phase
PCT applications are subject to specific
deadlines for entry into the national phase, and some jurisdictions also
require documents to be filed in the local language.
In the United States, for example, the PCT
national phase generally follows a 30-month deadline from the priority date,
and an English translation of the international application is required when
the application was not filed in English.
Working backward from the filing deadline,
rather than starting the language process only when the deadline is
approaching, gives the project much more room for proper review and
coordination.
6.3. Before Patent Assets Start Being Reused Frequently
As an innovative drug enters more markets
and accumulates more related patents, the same set of technical terms will
appear again and again across different documents.
Starting to build a terminology base and
reconcile historical translations only at that stage is usually far more
difficult than putting those systems in place from the beginning.
This is why the conversation around
pharmaceutical patent translation has changed.
The questions used to be relatively simple:
Which provider can translate the fastest?
How much will it cost?
Today, a more important question is whether
the language assets can stay with an innovative drug throughout its global
lifecycle.
From the initial patent filing to
License-out due diligence, national-phase entry, regulatory submissions, and
ongoing IP management, can the same technology remain clear, consistent, and
traceable across different languages?
As Chinese innovative medicines enter
global markets more frequently, pharmaceutical patent protection and overseas
IP strategy are receiving growing attention.
For companies, multilingual patent planning
is not simply about preparing several documents in different languages.
What matters more is preserving the
original technical meaning and scope of patent protection as an innovation
moves into different countries, different stages, and different languages.
Patent translation is only one part of that
process.
The larger task is to build a patent
language framework that can stay with an innovative drug throughout its journey
into global markets.
